Podcasts about ADT

Jessica Swank, Chief People Officer at Box, joined us on The Modern People Leader. We talked about building an "org brain", preparing managers to lead teams of humans plus agents, avoiding agent sprawl and tech debt, and why every people leader needs to start experimenting with AI personally to stay ahead.----  Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode269Sponsor Links:

Winter is tough for home inspectors, but it doesn't have to be. In this episode, Mike Crow shares a simple, proven strategy to help you stay profitable during the slow months by adding a referral stream through Secure24.He's joined by Trandon, who supports over 150 inspection companies nationwide and helps them earn a few hundred to several thousand dollars a month by connecting clients with ADT security systems. Mike also shares how this strategy is not just about extra income, but how it can actually help you book more inspections.If you want to hit March 1st with momentum, now is the time to act.Get your tickets to Mission 26 and have your best year ever!Mission 26 Unlock the Power of Mike's #1 Referral-Generating Marketing SystemGet full details here... BBM+ Who is Mike Crow?Mike Crow is a Marketing and Business Expert who has built and managed multiple 7-figure businesses, including two 7-figure inspection firms.For the past 15 years, he's coached thousands of other inspection business owners and has personally helped 100+ companies grow to $1,000,000+ in annual revenue. He has also helped multiple single-inspector operations earn 6-figure annual revenues (some surpassing $300,000).Mike can teach any entrepreneur how to systematize and market their business to achieve their personal and professional goals.

We dug into Foursquare's North Stars of vibrancy and velocity, applying design thinking to the people function, and their team-based performance model.---- Downloadable PDF with top takeaways: https://modernpeopleleader.kit.com/episode268Sponsor Links:

How do you confront your MIL? How do you back out of a wedding? How do you sleep with a newborn? These are questions that Jon and Alex try to answer on this week's episode. With little to no sleep, our new parents tackle wedding woes, passive-aggressive mother-in-laws, and a cake story that will might make you never trust a bakery again. But on a brighter note, Koby is in physical therapy! So the gang is doing alright…they could just use more sleep. Submit your questions here!⁠0:00 - Intro34:36 - Do I Get Them A Gift?39:28 - We Caught Her Stealing!42:47 - GBF Wedding44:25 - My Friend Confessed His Love For Me47:47 - I Need To Back Out of a Wedding50:31 - How Do I Uninvite a Bridesmaid?55:09 - My Best Friend's Third Wedding01:02:18 - My MIL Wore White To My Wedding01:08:11 - Reading Your Secrets01:09:17 - Recs of the WeekADT: Visit https://ADT.com or call 1-800-ADT-ASAPPerelel Health: New customers can enjoy 20% off their first order with code: STRAIGHT. Visit https://perelelhealth.comWayfair: Head to https://wayfair.com now to shop Wayfair's Black Friday deals for up to 70% off.Neiman Marcus: If you're looking for gifts that are guaranteed to surprise and delight, head to Neiman Marcus.Hexclad: Take 10% off at hexclad.com/STRAIGHT and cook like a pro all holiday long. Skims: If you're looking for the perfect gifts for everyone on your list - the SKIMS Holiday Shop is now open at https://SKIMS.com.Branch Basics: For a limited time only, our listeners get 15% off and Free Shipping on their premium starter pack when you use code STRAIGHT at https://BranchBasics.com/STRAIGHT. Visit our website ⁠www.giveittomestraightpodcast.com⁠Visit our other website ⁠www.alexjon.com⁠⁠Podcast⁠⁠Alex⁠⁠JonSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shannon Hobbs, Chief People Officer at BNY, joined us to unpack how the bank is scaling its early-career pipeline, flattening org design, and running a culture-first transformation.We discussed BNY's in-house AI hub “Eliza” (99% employee certification, 15k+ agents, 100 digital employees), plus practical advice for CHROs on building AI capability safely and at scale.---- How BNY is betting big on early talent (PDF): https://modernpeopleleader.kit.com/episode267Sponsor Links:

Luke O'Mahoney, Founder & Creator of Sapienˣ, joined The Modern People Leader.We talked about the three emerging models of product-led HR, Agile theater, and how an enterprise company phased its shift to product-led HR.---- Sponsor Links:

In today's episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.

Dr. Geo speaks with cancer immunologist Matthew Halpert, PhD about Immunocine, a dendritic-cell platform that “double-loads” patient-specific tumor signals to trigger a strong, physiologic immune response. Discussion includes mechanism, prostate cancer cases, how it can complement ADT and focal radiation, eligibility, workflow, and access.Chapters00:00 How the Immune System Fights Prostate Cancer02:00 Why dendritic cells matter; generals vs NK/T “soldiers”07:00 The “double-loading” breakthrough and fail-safe concept14:00 Trials in difficult cancers; safety and early signals18:00 Prostate cases: CRPC responses; lesions regressing22:00 Combining with ADT and focal radiation; timing27:00 Critical need for viable tissue; preservation tips34:00 Patient journey: review → tissue + apheresis → 3 doses/6 weeks41:00 Peri-lymphatic delivery; what patients feel; follow-up/boosts49:00 Cost, access, insurance help; foundations; closing takeawaysKey TakeawaysDendritic cells orchestrate immunity; NK/T cells execute.Precision double-loading overcomes a built-in fail-safe to amplify activation.Tissue access and preservation are essential for a broad, personalized target set.Pragmatic combination care: ADT and selective radiation can create a therapeutic window and enhance antigen presentation.________________________

Darren Murph, a leading voice on distributed work and former leader at GitLab, Zillow, and Andela returned to the show.We dug into the remote first maturity scale, the four-pillar operating model (knowledge, project, self, performance), and how to build an “org brain.”---- Sponsor Links:

Disciplined, purpose-driven innovation, anchored in governance, data, and the human experience, beats shiny-object hype.In this mega-episode, Lisa Fry, Chief Strategy & Innovation Officer at SCP Health, discusses “purposeful innovation” that reduces clinician burden and elevates patient experience: ED-volume prediction to align coverage, early pilots of ambient scribing, and patient-preferred models like hospital-at-home. She explains the guardrails, an enterprise architecture review board, commitments to core platforms, and stage-gated pilots with predefined success metrics, to avoid the “tyranny of the urgent” and scale only what works. Nancye Feistritzer, DNP, RN—VP, Center for Care Delivery & Innovation at Emory Healthcare, talks about how bold initiatives, including the Apple hospital work and implementing Epic on Apple devices, succeed only when they explicitly align with an organization's strategy, mission, and values. Nick Yaitsky, Board Member for TAG Digital Health, urges outcome-first AI roadmaps: accept that healthcare data is imperfect, mitigate bias by fine-tuning models to local populations and even individual patients, and build trust in the same way we came to trust GPS, through consistent, measurable results and governance. Olga Ryzhikova, Founding Partner at Kepler Team, tackles adoption by starting integration where clinicians work (SMART on FHIR/SSO), designing modern user experiences, and favoring ambient, low-click workflows so tools remain in use. Ron Strachan, Global Healthcare CIO Advisor, addresses rural access, noting that resilient, low-bandwidth virtual care and platform economies can “meet patients where they are.” His own brain-tumor journey underscores how imaging precision and reliable infrastructure can change outcomes. Finally, Wes Whitaker, AVP of Growth Strategy & Data Analytics, shows population health at scale: unifying EHR, eligibility, claims, and ADT into a modern cloud/Databricks stack, then applying predictive models to anticipate ER visits, target outreach, drive attribution, and prove ROI, while tightening security with role-based access. Together, their message is clear: govern hard, integrate early, pilot fast, measure relentlessly, and scale empathetically. Tune in and learn how to innovate with rigor, scale with empathy, and deliver measurable value!ResourcesConnect with Lisa Fry on LinkedIn here.Follow SCP Health on LinkedIn here and visit their website here.Follow and connect with Nancye Feistritzer on LinkedIn.Learn more about Emory Healthcare on LinkedIn and their website.Connect with and follow Nick Yaitsky on LinkedIn.Discover more about the TAG Digital Health Society on LinkedIn and explore their website.Follow and connect with Olga Ryzhikova on LinkedIn.Learn more about the Kepler Team on their LinkedIn and explore their website.Connect with Ron Strachan on LinkedIn here.Explore Zoom's website and learn more about them on their LinkedIn.Follow and connect with Wes Whitaker on LinkedIn.Discover more about Premise Health on their LinkedIn and visit their website.

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care. Episode Highlights: ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved radiographic progression-free survival when combined with ADT and ARPIs. Capitello-281: Highlights the use of Capivasertib in patients with PTEN loss, showing significant improvements in radiographic PFS. Potomac: Examining the role of durvalumab + BCG in high-risk non-muscle invasive bladder cancer, and the promising results from the Keynote 905 study involving enfortumab and pembrolizumab. IMVigor011: Delved into showcasing how ctDNA-guided therapy with atezolizumab can improve survival outcomes. Stay tuned as we navigate the complexities of treatment options, side effects, and the importance of patient-centered decision-making in oncology.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights! #ESMO2025 #GUOncology #LutetiumPSMA #Enfortumab #BladderCancer #ProstateCancer #OncologyBrothers

Brandon Weber, Co-founder & CEO of Nava Benefits, joined us on The Modern People Leader.We talked about why benefits have become the second-largest company expense — and how HR can “moneyball” their healthcare spend, cut down on benefits-related admin work, and deliver better employee outcomes through the emerging “alt marketplace.”---- Nava Links:

Hot off the press in the Presidential Plenary at #ESMO25, we chat with Dr Scott Tagawa (Weill-Cornell, USA) about the positive data he just presented from the PSMAddition trial. This is an eagerly awaited phase III randmosied trial of patients with mHSPC, to see if the addition of six cycles of Lu-PSMA-617 to a control arm of ADT and an ARPI, could improve rPFS and other endpoints. We are also joined in the studio by Prof Michael Hofman (Peter MacCallum Cancer Centre, AUS), co-PI of the UpFront PSMA trial which also explored a similar concept, plus some comments from our other colleague, prof Arun Azad, who was the Discussant in the Presidential at ESMO25. Declan Murphy hosting GU Cast solo today while Renu Eapen was in the OR doing surgery. Even better on our YouTube channelThis is a Themed Podcast supported by our Silver Partners, Novartis.

AI has existed for decades, but modern deep learning is finally delivering precision decisions in clinic. Dr. Spratt details how ArteraAI's predictive biomarker—validated on long-term randomized data—can spare roughly two-thirds of eligible men from ADT without compromising outcomes. We unpack ADT's quality-of-life trade-offs, practical training and nutrition strategies to preserve muscle, and where AI is headed next (post-surgery models, higher-risk disease). You'll also hear a clear framework for shared decision-making so men are treated as people, not just numbers.Key Points✅ AI meets prostate cancer. ArteraAI, developed by Dr. Daniel Spratt's team, is now part of the NCCN guidelines—helping doctors know which patients truly benefit from hormone therapy.✅ Two-thirds can skip ADT. Long-term data from the RTOG 9408 trial show most men can avoid the side effects of hormone therapy without affecting outcomes.✅ Quality of life first. Treatments should improve survival or well-being—if they don't, they shouldn't be used.✅ Lifestyle still matters. Exercise, protein, and resistance training help men on ADT preserve muscle and energy.✅ The future is personalized. New AI models will soon guide therapy for higher-risk patients and integrate full-body health data for truly tailored care.⏱️ Time-Stamped Highlights00:00 – Why AI in prostate cancer now? From buzzword to bedside with ArteraAI.01:30 – Deep learning vs. “human-defined” inputs; beyond Gleason to hundreds of slide features.03:10 – Landmark validation: RTOG 9408 and how the model predicts who benefits from ADT.05:00 – ADT trade-offs: longevity vs. libido, energy, bone/muscle; treat only if it improves life or survival.07:15 – “Exercise is medicine”: the 10-minute rule, protein targets, and resistance training on ADT.09:00 – Current indication: primarily intermediate-risk (Gleason 7) men receiving radiation.10:45 – What's next: models for higher-risk and post-prostatectomy patients; shorter-course ADT questions.13:00 – “Black box” & explainability: why robust external validation matters for trust.15:10 – Access & coverage: ordering via online portal; CMS coverage; what patients can ask their doctors.17:20 – Shared decision-making: reduce PSA anxiety; treat the person, not the number.___________________________________

Andrew Golden, Chief People Officer at RetailNext, joined us on The Modern People Leader.We talked about how he's driving transformation, why HR and IT must partner more closely, the power of building lightweight AI solutions in-house, and why he's optimistic about the future of people teams.---- Sponsor Links:

Gena Smith, CHRO at LVMH North America, joined us on The Modern People Leader. We talked about how she sparked an AI transformation across 75 LVMH brands, why HR should lead AI change management, and how to reframe AI adoption as a cultural and creative advantage.---- Sponsor Links:

What happens when you put a mic in front of HR leaders and ask them for their unfiltered takes on AI?In this episode, Daniel and Stephen recap their trip to HR Tech — where they recorded 12 quick-hit “AI Confessions” from folks they met on the conference room floor. From agentic workflows and custom GPT chaos to the real blockers slowing down AI adoption, this one's packed with candid insights from the front lines.You'll hear what HR leaders from companies like Lumen, Articulate, and Airbnb.---- Sponsor Links:

Angela Crossman, Hernan Chiosso, and Jean-Luc Charles joined us to debrief the “Yellow Pod” conversation from MPL Live NYC and what the group is actually doing with AI at work. We covered opportunities vs blockers, “AI as coach” guardrails, why HR should own enablement, actionable next steps, and predictions for the AI-powered workplace.---- Sponsor Links:

They started off by introducing themselves as The Three Horsemen of the Apocalypse - what could possibly go wrong!! Declan couldn't resist the opportunity to invite three very eminent radiation oncologists into the studio when they all happened to be in Melbourne, even if he was particularly outnumbered while Renu was away! Vedang Murthy (Tata Memorial, India), Andrew Loblaw (Sunnybrook Hospital, Canada), and Sarat Chander (Peter Mac, Melbourne) are all highly specialised in prostate radiation, so Declan invited them into the GU Cast studio to pick their brains on three big areas in prostate radiation:1. Hypofractionation in 2025 - Who and How?2. Who needs ADT and for how long when having prostate radiation?3. Metastasis-directed therapy for oligometastatic disease - is there any point??Tune in to find out how Urologist Declan Murphy fared up against these three Radiation Oncologists!!! Even better on our YouTube channelThis podcast is supported by our Bronze Partner, Icon Cancer Centre.

"We just want our daughter's remains returned so we can have some closure to our grief."On 15 August 2015, employees at the Mission Park Funeral Chapels North in San Antonio, TX closed up for the evening. They'd just held a service for a young woman named Julie Mott who had perished after a lifelong battle with cystic fibrosis. By 4:30 PM that Saturday, the doors were locked and the ADT alarm system was set.When staff returned to the facility the following morning, they were surprised to see that Julie's casket had been moved from an empty hallway and now rested in a strange position near an exit door. And inside the casket, there was nothing. Her remains were missing...Research by Ira RaiWriting by Amelia WhiteHosting & production by Micheal WhelanLearn more about this podcast at http://unresolved.meIf you would like to support this podcast, consider heading to https://www.patreon.com/unresolvedpod to become a Patron or ProducerBecome a supporter of this podcast: https://www.spreaker.com/podcast/unresolved--3266604/support.

Can high-precision radiation change how we treat metastatic prostate cancer? In this episode, I'm joined by Ronald C. Chen, MD, MPH—radiation oncologist, national guideline author (AUA/ASCO), and clinical-trial leader with 170+ publications—to unpack stereotactic body radiation therapy (SBRT) for disease that has spread to lymph nodes, bones, and beyond. We get practical about who benefits, where SBRT shines, and how to balance treatment intensity with quality of life.SBRT offers highly focused, short-course radiation that can control limited (“oligo-”) metastatic prostate cancer and delay systemic therapy for many men. Dr. Chen explains when to treat individual nodes/bone lesions versus comprehensive nodal fields, how anatomy determines dose/fraction choices (often 3–5 treatments), and why modern SBRT sometimes reduces the need for concurrent hormone therapy. We cover salvage options after prior radiation (brachytherapy seeds, HIFU, cryo, repeat SBRT, or salvage prostatectomy), the role and limits of PSMA PET, fracture risk and bone health (DEXA), and the evolving data—including the large NRG-GU013 trial—for higher-risk disease. Throughout, we emphasize shared decision-making, realistic expectations, and considering clinical trials when data are evolving.00:00 – Can SBRT change metastatic prostate cancer care? Meet Dr. Ron Chen.01:00 – Disclaimer: Views are Dr. Geo's and guests'—independent of NYU Langone.07:00 – Recurrence scenarios: prostate-only, nodal, or bone/other; why catching early matters.12:00 – Five salvage options after prostate radiation: seeds (brachytherapy), HIFU, cryo, SBRT (focal or whole-gland), or salvage prostatectomy.19:00 – Nodal relapse: treat all pelvic nodes + ADT ± abiraterone vs. SBRT to a few nodes only—how patient priorities drive the plan.26:30 – Oligometastasis: SBRT alone can control disease for many men ~2+ years on average, delaying hormones.30:00 – Fractions: why 3–5 treatments is typical and how adjacent bowel/organ anatomy sets the pace.31:00 – SBRT in 2 fractions for select primary cases looks promising; high-risk SBRT under study (NRG-GU013).37:00 – Bone mets: SBRT preferred; understanding fracture risk (tumor size, dose, shrinkage).40:00 – DEXA before ADT; spine SBRT can spare the spinal cord with modern planning.48:00 – Clavicle/hilar nodes: SBRT near lung/heart/esophagus—safe with careful dose constraints.56:00 – Why clinical trials matter for “how long on hormones?” and other open questions.57:00 – Soft-tissue mets (liver/brain): SBRT can help, often alongside systemic therapy.59:00 – Parting advice: early detection, close follow-up, and hopeful trajectory of care.___________________________________

Joy Rothschild, Chief Human Resources Officer at Omni Hotels & Resorts, joined us on The Modern People Leader. ---- Sponsor Links:

Jessica Zwaan joins MPL Build to show HR leaders how to craft business cases that CEOs actually approve, using BLUF, the So What test, and clear links to revenue and savings. We walk through conservative projections, objection handling, and a live role-play on adopting a performance platform in today's fiscally skeptical environment.---- Sponsor Links:

Is androgen deprivation therapy (ADT) always necessary when prostate cancer patients undergo radiation? And if so, for how long—six months, a year, two years? In this insightful conversation, Dr. Geo sits down with Dr. Nima Aghdam, radiation oncologist at NY CyberKnife and NYU Langone, to explore the evolving role of ADT in prostate cancer treatment.Dr. Aghdam shares his expertise on advanced radiation techniques like SBRT, personalized approaches to ADT duration, and the importance of lifestyle interventions. Together, they highlight how individualized care can improve survival, minimize side effects, and help men thrive beyond diagnosis.If you or a loved one are facing decisions about radiation and hormone therapy for prostate cancer, this episode offers clarity, evidence-based guidance, and hope.Radiation vs. Surgery: Both are highly effective; choice often comes down to quality-of-life goals and patient preference.Lymph Node Positive Disease: Options include focal SBRT or comprehensive external beam therapy; treatment decisions must balance efficacy and quality of life.Lifestyle's Role: Exercise and nutrition create a “hostile microenvironment” for cancer, improving both survival and side-effect management.Radiation Innovations: From rectal spacers to fewer treatment sessions (trials reducing SBRT from five to two fractions), techniques continue to evolve.ADT Considerations:Historically prescribed for up to 24–36 months with radiation.New genomic and AI-based classifiers may allow some men to stop ADT earlier (6–12 months).Balancing survival benefits with quality of life is critical.PSA Anxiety: PSA fluctuations don't always equate to recurrence or mortality. Context and long-term monitoring matter more than isolated numbers.Finding the Right Oncologist: Beyond equipment and technology, trust and honest communication with your doctor are essential.Timestamps00:00 – Introduction: Is ADT always necessary during radiation?05:00 – Radiation vs. surgery for localized and advanced prostate cancer.10:00 – Salvage options: what happens if radiation or surgery fails?13:00 – Treating prostate cancer with lymph node involvement.17:00 – Communicating metastasis risk and long-term outcomes to patients.18:30 – Lifestyle interventions as part of prostate cancer care.21:00 – Rectal spacers and preparation for SBRT.23:30 – Advances in SBRT: reducing from five fractions to two.25:30 – Understanding fractions, dosage, and radiation delivery.32:00 – Personalizing ADT: who benefits, and for how long?36:00 – Clinical trials on ADT duration (6, 12, 18, 24+ months).39:00 – Radiation's long-lasting effects and how ADT fits in.42:00 – PSA recurrence vs. actual risk of mortality45:00 – Patient anxiety and the psychological impact of PSA testing.47:00 – Exercise and lifestyle: evidence for improved survival.49:00 – Supplements, PSA manipulation, and misinformation.51:00 – How to choose a reputable radiation oncologist.56:00 – Evolving evidence: are radiation-related risks lower today?58:00 – Parting words: seeing prostate cancer as a chance for transformation.___________________________________

Kim Minnick, Founder of Code Traveller HR, joined us on The Modern People Leader.We dug into why performance reviews often fail, how companies can decouple performance from compensation, creative ways to reward employees beyond pay, and the importance of transparency, choice, and designing programs that reflect company values.---- Sponsor Links:

This episode of The Modern People Leader dives into the realities of leading through constant change, featuring guests Mita Mallick, Shelby Garrison, and Kelly Lohr. We discussed how HR leaders can navigate layoffs with transparency and humanity, the importance of supporting both exiting and remaining employees, and how to build resilience and adaptability into workplace culture.---- Sponsor Links:

Yemi Akisanya, Head of JEDI (Justice, Equity, Diversity, and Inclusion) at Axon, joined us on The Modern People Leader. We talked about how the DEI conversation is evolving post-2020, why quotas are being replaced with performance-aligned strategies, and how Axon is making inclusion measurable and mission-critical.---- Sponsor Links:

What if prostate cancer treatment weren't months of daily radiation—but five ultra-precise sessions guided in real time by MRI? Today, Dr. Michael J. Zelefsky (Professor of Radiation Oncology, NYU Grossman School of Medicine) explains how MRI-LINAC and adaptive planning are redefining accuracy, reducing side effects, and personalizing care. A pioneer behind IMRT and image-guided radiotherapy, Dr. Zelefsky breaks down SBRT vs. IMRT, protons vs. photons, HDR brachytherapy, when to add hormone therapy, and how genomics + AI are shaping what's next.In this conversation, Dr. Zelefsky charts the evolution from long-course radiation to short-course SBRT with outcomes comparable to 7–9 week regimens—thanks to precision imaging and planning. He clarifies where IMRT ends and SBRT begins, why protons haven't shown superiority over photons in prostate cancer, and where HDR brachytherapy (Ir-192) shines—especially as a boost in higher-risk disease. We dig into dose equivalence (why 5×8 Gy can match ~80–90 Gy long-course), risk-based treatment + ADT duration, and how Decipher/Artera scores can refine decisions. Most exciting: MRI-LINAC with continuous motion monitoring keeps the prostate in a virtual “bullseye,” enabling whole-gland treatment with focal boosts today—and potentially true focal therapy tomorrow as biologic imaging and AI mature.Time-Stamped Highlights00:00 – Welcome 02:00 – Why Dr. Zelefsky's work is so respected; career arc and impact04:00 – What changed: CT/MRI planning → 3D-CRT → IMRT → SBRT12:45 – IMRT vs. SBRT: definitions, session counts, who gets what19:10 – Energy sources overview: photons, protons, brachytherapy20:30 – Protons vs. photons: evidence, indications, cost, access24:00 – HDR brachytherapy (Ir-192) as a temporary “in-and-out” boost28:00 – Dose logic: why 5×8 Gy (~40 Gy) ≈ long-course 80–90 Gy29:30 – Risk groups (low/intermediate/high) and when ADT is crucial33:00 – ADT durations (6–36 months): what trials actually showed37:00 – Genomics (Decipher/Artera): resolving risk discrepancies39:00 – What MRI-LINAC adds: real-time adaptive planning43:00 – Continuous Motion Monitoring (CMM): beam stops if target moves47:00 – Treat whole gland + boost the DIL (FLAME study approach)49:00 – Toward focal therapy with better biologic imaging + AI54:00 – How to choose: values, side-effects, lifestyle, comorbidities01:01:00 – Final guidance: don't be overwhelmed—multiple good option

Sarah opens up about starting opioids at 20, a rapid slide to heroin, pregnancy on methadone, jail, and the drug court program that helped her turn it around. After a later Xanax relapse during COVID, she did the work—therapy, structure, and service—and is now certified and working as a counselor at a maintenance clinic. This candid conversation with Wendy Beck and Rich Bennett shows what sustainable recovery really looks like—and why hope matters. Sponsored by Rage Against Addiction Guest Bio:  Sarah is a Harford County native, mom, and recovery professional. After entering opioid use at 20 and escalating to heroin in 2012, she experienced jail and drug court, achieved long-term abstinence from opiates and cocaine (since Sept. 27, 2016), overcame a benzodiazepine relapse in 2020–2021 (clean since Nov. 4, 2020), earned her Peer Recovery Specialist credential and ADT approval, and now counsels patients at a medication-assisted treatment clinic. Main Topics: ·         Podathon for Recovery: 12 Days of Hope benefiting Rage Against Addiction·         Starting opioids at 20; rapid progression from pills to heroin (2012)·         Pregnancy on methadone, stigma, and learning MAT safety·         IV use, crack/cocaine, legal consequences, and visible decline·         Jail detox and entry into Drug Court; Judge-led accountability·         Long-term sobriety from opiates/cocaine; COVID-era Xanax relapse and dangers of benzo withdrawal·         Therapy, boundaries, routines, fitness, and gratitude as core recovery tools·         Working in recovery: peer support vs. clinicians; women-specific needs; mom guilt and shame·         Maintenance meds (methadone/Suboxone): misuse stigma vs. real stability·         Parenting conversations about peer pressure and openness with kids·         Burnout prevention for recovery workers (self-care, phone boundaries, weekly therapy)  Resources mentioned: ·         Donate to Rage Against Addiction ·         Center for ASend us a textDonate HereRage Against AddictionRage Against Addiction is a non-profit organization dedicated to connecting addicts and their familiDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showRate & Review on Apple Podcasts Follow the Conversations with Rich Bennett podcast on Social Media:Facebook – Conversations with Rich Bennett Facebook Group (Join the conversation) – Conversations with Rich Bennett podcast group | FacebookTwitter – Conversations with Rich Bennett Instagram – @conversationswithrichbennettTikTok – CWRB (@conversationsrichbennett) | TikTok Sponsors, Affiliates, and ways we pay the bills:Hosted on BuzzsproutSquadCast Subscribe by Email

Experts from UCSF outline the latest treatments and research for advanced prostate cancer, highlighting improved outcomes and promising therapies. Dr. Kelly Fitzgerald reviews intensified androgen deprivation therapy (ADT) and the evolving role of imaging, triplet therapy, and local treatments. Dr. Ivan de Kouchkovsky shares how radioligand therapies like Lutetium-177 PSMA target cancer with precision and are now approved earlier in care. Dr. David Oh explains immunotherapy strategies, including cancer vaccines and checkpoint inhibitors, and explores new options like bispecific T-cell engagers. Dr. Terry Friedlander discusses bone health and the impact of hormone therapy, offering strategies to reduce fracture risk and improve quality of life. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40868]

Experts from UCSF outline the latest treatments and research for advanced prostate cancer, highlighting improved outcomes and promising therapies. Dr. Kelly Fitzgerald reviews intensified androgen deprivation therapy (ADT) and the evolving role of imaging, triplet therapy, and local treatments. Dr. Ivan de Kouchkovsky shares how radioligand therapies like Lutetium-177 PSMA target cancer with precision and are now approved earlier in care. Dr. David Oh explains immunotherapy strategies, including cancer vaccines and checkpoint inhibitors, and explores new options like bispecific T-cell engagers. Dr. Terry Friedlander discusses bone health and the impact of hormone therapy, offering strategies to reduce fracture risk and improve quality of life. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40868]

Experts from UCSF outline the latest treatments and research for advanced prostate cancer, highlighting improved outcomes and promising therapies. Dr. Kelly Fitzgerald reviews intensified androgen deprivation therapy (ADT) and the evolving role of imaging, triplet therapy, and local treatments. Dr. Ivan de Kouchkovsky shares how radioligand therapies like Lutetium-177 PSMA target cancer with precision and are now approved earlier in care. Dr. David Oh explains immunotherapy strategies, including cancer vaccines and checkpoint inhibitors, and explores new options like bispecific T-cell engagers. Dr. Terry Friedlander discusses bone health and the impact of hormone therapy, offering strategies to reduce fracture risk and improve quality of life. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40868]

Experts from UCSF outline the latest treatments and research for advanced prostate cancer, highlighting improved outcomes and promising therapies. Dr. Kelly Fitzgerald reviews intensified androgen deprivation therapy (ADT) and the evolving role of imaging, triplet therapy, and local treatments. Dr. Ivan de Kouchkovsky shares how radioligand therapies like Lutetium-177 PSMA target cancer with precision and are now approved earlier in care. Dr. David Oh explains immunotherapy strategies, including cancer vaccines and checkpoint inhibitors, and explores new options like bispecific T-cell engagers. Dr. Terry Friedlander discusses bone health and the impact of hormone therapy, offering strategies to reduce fracture risk and improve quality of life. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40868]

Jessica Zwaan, Author of Built for People & COO at Talentful, joined us on The Modern People Leader.We talked about AI adoption in HR, from policy design to hands-on building. We explored the “Wild West” of AI use, tool selection, overcoming the stigma of ‘cheating,' and practical frameworks like the 4Bs (Bot, Build, Borrow, Buy) to guide adoption and innovation.---- Sponsor Links:

Pilar Muner, VP of People & Talent at ChartHop, joined us on The Modern People Leader.We covered:- Why fractional work isn't always the burnout cure-all it's made out to be-How ChartHop is using AI to power HR workflows in-house- The AI vendor checklist every HR leader needs — what to ask, what to watch for, and how to cut through the hypeIf you're evaluating AI tools for your people team, this episode will give you a practical lens on security, data integrity, and what to prioritize in vendor selection.---- Sponsor Links:

In today's episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California. In our conversation, Dr Dorff discussed the role of ADT in prostate cancer management, highlighting where this class of agents fits into National Comprehensive Cancer Network guidelines and how this class has evolved with the development of LHRH antagonists and agonists. She explained how the observational OPTYX study (NCT05467176), a registry of relugolix (Orgovyx) use, aims to address safety and efficacy in combination with androgen receptor pathway inhibitors in patients with advanced prostate cancer. She also noted how early data from OPTYX presented at the 2025 ASCO Annual Meeting showed relugolix's use in localized and metastatic settings. Dorff also talked through relugolix's safety profile, particularly regarding cardiovascular risk, as well as the quality-of-life effects associated with ADT. She also addressed strategies to mitigate financial toxicity, along with the potential for future ADT-sparing treatments.

Facing a rising PSA can be unsettling. But is early castration really the answer? In this episode, Dr. Stephen Petteruti walks through the harsh truth about androgen deprivation therapy (ADT), commonly known as medical castration. While often prescribed when PSA levels rise, he cautions that this drastic intervention is not without cost: loss of libido, cognitive decline, bone fractures, cardiovascular risks, and more. Instead of rushing into ADT at the first sign of trouble, Dr. Stephen urges a symptom-driven approach. He blends evidence, philosophy, and real-world experience to help men make smarter, more humane decisions at the edge of life and medicine.Ready to take control of your health decisions? Rethink what real prostate cancer care can look like. Tune in now: When Is Castration Worth Doing?Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

JooBee Yeow joined us on The Modern People Leader to talk about why HR must stop overfunctioning and start diagnosing real business problems—especially when revenue is on the line. We discussed how HR leaders can step out of their silo, challenge assumptions, influence revenue growth, and flip the HR pyramid to prioritize high-impact, strategic work.---- Sponsor Links:

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Tiffany Stevenson, former Chief People Officer at WeightWatchers and Patreon, joined us on The Modern People Leader. We talked about this being the CHROs toughest chapter yet, how AI is reshaping HR, and what HR brings to the boardroom.---- Sponsor Links:

This week, Dr. Joel Kahn reviews the latest research on men's health, focusing on diet and prostate cancer. He highlights findings that support whole-food, plant-based diets and discusses the connection between prostate cancer, heart disease, and the cardiovascular risks associated with androgen deprivation therapy (ADT). Other topics covered include plant-based diets and disease rates, the role of LDL cholesterol in soft plaque formation, TMAO in abdominal aortic aneurysms and kidney disease, periodontal disease and its impact on heart health, saccharin and cardiovascular risk, extreme physical activity and carotid plaque, and the effects of Tylenol use during pregnancy.  Dr. Kahn also reviews new research on cyclodextrin suppositories, a paper examining the impact of statins on blood sugar, and the potential role of TUDCA as a possible antidote.  Resources mentioned in this episode include the cyclodextrin paper available at www.atherocare.com/drjoelkahn and details on TUDCA at https://shop.drjoelkahn.com/catalog/product/view/id/17560/s/tudca-tauroursodeoxycholic-acid-60-capsules/. Special thanks to our sponsor Igennus.com, use discount code DrKahn for all products.

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. Dr. Cornelia Ding explains how to read and understand a prostate cancer pathology report by breaking down its five key sections. Dr. Rahul Aggarwal explores how clinical trials improve prostate cancer care by advancing personalized treatment, increasing access, and correcting misconceptions about placebos. Dr. Jonathan Chou highlights the expanding role of precision medicine and how genetic insights guide individualized treatment based on each tumor's molecular makeup. Dr. Eric Small explains how androgen deprivation therapy (ADT) targets the cancer's dependence on testosterone and how newer therapies and combinations are improving outcomes, while also emphasizing the need to balance effectiveness with side effects through shared decision-making. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40865]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. Dr. Cornelia Ding explains how to read and understand a prostate cancer pathology report by breaking down its five key sections. Dr. Rahul Aggarwal explores how clinical trials improve prostate cancer care by advancing personalized treatment, increasing access, and correcting misconceptions about placebos. Dr. Jonathan Chou highlights the expanding role of precision medicine and how genetic insights guide individualized treatment based on each tumor's molecular makeup. Dr. Eric Small explains how androgen deprivation therapy (ADT) targets the cancer's dependence on testosterone and how newer therapies and combinations are improving outcomes, while also emphasizing the need to balance effectiveness with side effects through shared decision-making. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40865]

Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. Dr. Cornelia Ding explains how to read and understand a prostate cancer pathology report by breaking down its five key sections. Dr. Rahul Aggarwal explores how clinical trials improve prostate cancer care by advancing personalized treatment, increasing access, and correcting misconceptions about placebos. Dr. Jonathan Chou highlights the expanding role of precision medicine and how genetic insights guide individualized treatment based on each tumor's molecular makeup. Dr. Eric Small explains how androgen deprivation therapy (ADT) targets the cancer's dependence on testosterone and how newer therapies and combinations are improving outcomes, while also emphasizing the need to balance effectiveness with side effects through shared decision-making. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40865]

Priscila Bala, CEO of LifeLabs Learning, joined us on The Modern People Leader.We explored how AI is transforming learning, the enduring role of middle management, and why the most impactful leadership skills are more human than ever.---- Resources Mentioned:

This week on The Vergecast, the co-founder and former CEO of iRobot, Colin Angle, joins The Verge's smart home reviewer, Jennifer Pattison Tuohy, to discuss what the ideal home robot is. Are we close to creating a Rosie the Robot — an all-in-one humanoid robot that can take care of our homes, or should we take an entirely different approach to home robotics? They dive into the advances in technology powering this shift and ponder what purpose robotics in the home should really serve. Then, Jen takes a journey back into smart home history to help us understand its future. Grant Erickson, Principal of Nuovations, a former Apple, Nest, and Google engineer who was part of the team that developed Thread, joins the show. He shares the story of how and why, back in 2011, the Nest team, led by Tony Faddell and Matt Rogers, decided to create a smart home protocol. It involves a thermostat, fragmented ecosystems, and one of the best smart home products ever made. They discuss how Thread became the foundation of the Matter smart home standard — an unprecedented industry collaboration with a herculean task — to make the smart home simpler. To close out the show, Grant sticks around to help answer a Vergecast hotline question (call 866-VERGE11 or email vergecast@theverge.com) about how Matter manages your data. Further reading: Maybe I don't want a Rosey the Robot after all Amazon left Roomba with a huge mess to clean up Figure will start ‘alpha testing' its humanoid robot in the home in 2025 Amazon Astro review: too much Alexa, not enough arms Samsung is finally releasing Ballie This Pixar-style dancing lamp hints at Apple's future home robot iRobot's founder is working on a new kind of home robot iRobot OS is the newest ‘brain' for your Roomba Amazon bought iRobot to see inside your home I tested a robot vacuum with an arm, and my dog may never forgive me Inside the Nest: iPod creator Tony Fadell wants to reinvent the thermostat Nest CEO Tony Fadell on Google acquisition Fire drill: Can Tony Fadell and Nest build a better smoke detector? How big companies kill ideas — and how to fight back, with Tony Fadell Situation: there are too many competing smart home standards Matter's plan to save the smart home Nest's home security system costs $499 and comes with magnetic door sensors Google says Matter is still set to fix the biggest smart home frustrations Thread is Matter's secret sauce for a better smart home Nanoleaf launches a smart switch after eight years of trying Thread count: Ikea is stitching together a smarter home Why Thread is Matter's biggest problem right now The four changes in Thread 1.4 that could fix the protocol It could be 2026 before all your Thread border routers work together Matter will be better in 2025 — say the people who make it The Nest Learning Thermostat gets its biggest upgrade in over a decade killedbygoogle.com Google's ADT partnership finally has a new home security product to show for it Google discontinues Nest Protect smoke alarm and Nest x Yale door lock Google discontinues its Google Nest Secure alarm system Appliance makers are teaming up to reduce your electricity usage — and save you cash Learn more about your ad choices. Visit podcastchoices.com/adchoices

Rajia Abdelaziz is the CEO and co-founder of invisaWear, a company at the forefront of smart jewelry and life-saving technology. An advocate for women's and children's safety, Rajia scaled invisaWear to reach over 100,000 customers, successfully raised millions of dollars, and earned coveted recognition including Forbes' 30 Under 30 North America, Boston Globe's Tech Power Players, BostInno's 25 Under 25, and the New England Innovations Award. Just last week invisaWear was selected by Oprah Winfrey for this year's Back to School List. As a minority female CEO, Rajia is passionate about mentoring other young entrepreneurs to pursue their dreams and beat the odds, guiding aspiring entrepreneurs at UMass Lowell's Entrepreneurship program.

Help MuggleCast grow! Become a MuggleCast Member and get great benefits like Bonus MuggleCast! Patreon.com/MuggleCast  Grab official merch! MuggleCastMerch.com Pick up overstock merch from years past, including our 19th Anniversary Shirt! MuggleMillennial.Etsy.com On this week's episode, news continues to roll in on the new Harry Potter TV Show. Join Andrew, Eric, Micah and Laura as they talk the latest casting news and first looks before busting open the MuggleMail bag to take your feedback on the last few chapters of Order of the Phoenix! News: Our first look at Dominic McLaughlin as The Boy Who Lived and Nick Frost as Hagrid! Plus, four new casting announcements: Rory Wilmot as Neville Longbottom, Amos Kitson as Dudley Dursley, Louise Brealey as Madam Rolanda Hooch, and Anton Lesser as Garrick Ollivander. And those Dursleys are looking mighty 90s in these behind-the-scenes photos! Voicemails cover Snape's Worst Memory, Harry's Career Aspirations, Grawp and how the Pensieve could have altered the end of Order of the Phoenix! Why is Harry so obsessed with Dumbledore? He barely knows the guy! How exactly did Tom Riddle's curse on the Defense Against The Darks Arts position work? Old habits die hard! Did Rita Skeeter actually turn over a new leaf? One listener questions if there really was a binding magical contract with the Goblet of Fire or if it was all secretly part of Dumbledore's larger plan! Put your memories away! Did Snape bait Harry to look in the Pensieve? Were Hermione's comments about Firenze really a commentary on Lavender and Parvati's fawning over their new Divination teacher? Comparing the Marauder's treatment of Snape to the Death Eaters treatment of the Roberts family Reducto! Why couldn't Voldemort just shrink himself to gain access to the Ministry and get the prophecy himself? Chicken Soup For The MuggleCast Soul Chapter-by-Chapter returns next week with Order of the Phoenix, Chapter 33: Fight and Flight Quizzitch: In this chapter Umbridge placed Stealth Sensor Spells around her office door. Founded by Edward Calahan over 150 years ago, the company which currently holds at least 15% of the market share for home security systems, is called ADT. What does ADT stand for? Join in on the fun! In this week's Bonus MuggleCast, we look back at the Summer of Potter - 2007 saw the release of both Deathly Hallows and the Order of the Phoenix movie! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of the Drop In CEO podcast Errol Allen shares insights on helping C-Suite leaders and organizations enhance their process efficiency, reduce costs, and achieve better business outcomes. Errol delves into the importance of process documentation, the role of CEOs in leading these initiatives, and the benefits of thorough documentation for training and internal operations. Highlighted is a case study where Errol helped a company streamline operations, resulting in improved morale, better performance, and increased company value. Tune in to learn how to overcome resistance in process documentation and when to consider automation for optimal efficiency. Episode Highlights: 02:15 Errol's Personal and Professional Journey 10:27 The Importance of Process Documentation 21:22 Navigating Resistance and Achieving Buy-In Errol Allen is a process improvement and systems expert who helps organizations align people, processes, and technology for better efficiency and ROI. With a hands-on approach shaped by roles at companies like ADT, GEICO, and The Houston Post, Errol launched his consulting business in 2011 to pursue his passion for smart systems and stellar service. He facilitates cross-functional process improvements across industries like property management, logistics, and manufacturing. A Houston native and natural storyteller, Errol’s insights have been featured in the Houston Business Journal, Customer Experience Magazine (UK), and more. His favorite saying? “I’m just having fun!” Connect with Errol Allen: LinkedIn: https://www.linkedin.com/in/errolallen/ Company Website: http://www.errolallenconsulting.com For more information about my services or if you just want to connect and have a chat, reach out at: https://dropinceo.com/contact/See omnystudio.com/listener for privacy information.

Help MuggleCast grow! Become a MuggleCast Member and get great benefits like Bonus MuggleCast! Patreon.com/MuggleCast  Grab official merch! MuggleCastMerch.com Pick up overstock merch from years past, including our 19th Anniversary Shirt! MuggleMillennial.Etsy.com On this week's episode, we discuss the events of Chapter 32 of Order of the Phoenix, "Out of the Fire." Join Andrew, Eric, Micah, and Pam as they cover the second attempted break-in to Professor Umbridge's office, and the fallout. Chapter-by-Chapter continues with Harry Potter and the Order of the Phoenix, Chapter 32: Out of the Fire Our Time Turner segment takes us back to Episode 470 of MuggleCast, titled “Silky Smooth Snape.” Should Harry have known that his vision was a ruse? The hosts go all-in on listing several signs, and whether they alone reveal the truth. Micah connects the threads between Sirius and Harry in books 3 and 5. What is Hermione getting at by mentioning Harry's 'saving people thing'? Often times, Harry has legitimately been left to fix the Hogwarts problem and save people. Can we blame him? We discuss the power lust present in both Umbridge and Draco, and how they need each other at this time. Umbridge's treatment of Snape is interesting, since she does trust he's as horrible as she is. What Hermione does works perfectly on Umbridge. Why? Why aren't the two other heads of House, Flitwick and Sprout, also members of the Order? Is Dumbledore skeptical of their loyalty, or is he just giving them a break?? The hosts have differing ideas about what being a 'bad mofo' means, when rating who the baddest was in this chapter. Our Lynx Line patrons answer the question, when was a time that you successfully thought on your feet the way Hermione does with Umbridge? Quizzitch: In this chapter Umbridge placed Stealth Sensor Spells around her office door. Founded by Edward Calahan over 150 years ago, the company which currently holds at least 15% of the market share for home security systems, is called ADT. What does ADT stand for? Join in on the fun! Learn more about your ad choices. Visit megaphone.fm/adchoices